By: John J Nemunaitis MD
Date: November 22, 2011 | Source: Mary Crowley Medical Research Center, Dallas, TX
Our understanding of the biomolecular basis of cancer has virtually exploded over the last 10 years. Developments in genetics, molecular biology, and molecular pharmacology promise to dramatically alter strategies of cancer treatment. Clearly, previous therapeutic principles derived from cytotoxic based therapy now provide diminishing return with respect to patient benefit.